- Report
- August 2024
- 150 Pages
Global
From €2619EUR$2,789USD£2,185GBP
- Report
- March 2026
- 136 Pages
France
From €3755EUR$3,999USD£3,132GBP
- Report
- May 2024
- 140 Pages
Global
From €3755EUR$3,999USD£3,132GBP
- Report
- May 2024
- 134 Pages
Global
From €3755EUR$3,999USD£3,132GBP
- Report
- August 2026
- 150 Pages
From €4460EUR$4,750USD£3,721GBP
- Report
- August 2026
- 70 Pages
Egypt
From €4460EUR$4,750USD£3,721GBP
- Report
- August 2026
- 70 Pages
South Africa
From €4460EUR$4,750USD£3,721GBP
- Report
- August 2026
- 70 Pages
South Korea
From €4460EUR$4,750USD£3,721GBP
- Report
- August 2026
- 120 Pages
Mexico
From €4460EUR$4,750USD£3,721GBP
- Report
- August 2026
- 70 Pages
Brazil
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Germany
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Italy
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Oman
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
France
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Russia
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Japan
From €4460EUR$4,750USD£3,721GBP
- Report
- October 2022
- 70 Pages
Africa
From €4460EUR$4,750USD£3,721GBP
- Report
- January 2025
- 140 Pages
Global
From €3709EUR$3,950USD£3,094GBP

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more